Quantcast

Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease - Preliminary prospective confirmatory trial.

Research paper by Norio N Akuta, Hiromitsu H Kumada, Shunichiro S Fujiyama, Yusuke Y Kawamura, Hitomi H Sezaki, Tetsuya T Hosaka, Masahiro M Kobayashi, Mariko M Kobayashi, Satoshi S Saitoh, Yoshiyuki Y Suzuki, Fumitaka F Suzuki, Yasuji Y Arase, Kenji K Ikeda

Indexed on: 31 Mar '18Published on: 31 Mar '18Published in: Hepatology Research



Abstract

The recurrence rates of pruritus after the stop of nalfurafine hydrochloride is unknown in chronic liver disease. A prospective confirmatory trial was performed to determine the recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease. After the pretreatment with nalfurafine hydrochloride for 4 weeks or more, 15 consecutive Japanese patients, who confirmed the improvement of pruritus (the decrease in Visual Analogue Scale (VAS) of 50 mm or more), were enrolled in the present study. Patients selected either of continuous group (continuation of nalfurafine hydrochloride for 4 weeks) and discontinuous group (stop of nalfurafine hydrochloride) at the time of consent to study protocol, by self-determination. The recurrence rates (the increase in VAS of 25 mm or more after the stop of nalfurafine hydrochloride) were 100% (5 of 5 patients) and 0% (0 of 10) in discontinuous and continuous group, respectively. In discontinuous group, 3 patients selected retreatment of nalfurafine hydrochloride as salvage therapy, and they generally recovered to the levels of VAS at the stop of treatment. The present prospective trial showed the high recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease. This article is protected by copyright. All rights reserved.

More like this: